Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Theriva Biologics, Inc. (TOVX)
Rockville, MD, US
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
Based on only 1 article — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.60% | -12.19% | +39.53% | +78.34% | +8.02% | +52.99% | -37.80% | -98.21% | -99.74% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+89.1% ★ Q1'26: +96.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%— Q1'26: -818.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%— Q1'26: -700.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-303.1% Q1'26: -276.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+800.6% Q1'26: +1,376.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.18× Q1'26: -0.25× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 21.75M (-100.0%)
|
—
est: 300.0K (-100.0%)
|
300.0K
300.0K – 300.0K
+0.0% YoY
|
—
— – —
-100.0% YoY
|
25.73M
25.73M – 25.73M
|
54.05M
54.05M – 54.05M
+110.1% YoY
|
154.40M
154.40M – 154.40M
+185.6% YoY
|
| EBITDA |
-19.29M
|
-14.91M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-19.43M
|
-15.02M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-25.65M
est: -292.71M (+91.2%)
|
-25.25M
est: -35.45M (+28.8%)
|
-2.73M
-2.73M – -2.73M
+92.3% YoY
|
-2.91M
-2.91M – -2.91M
-6.7% YoY
|
-3.89M
-3.89M – -3.89M
-33.3% YoY
|
-4.49M
-4.49M – -4.49M
-15.6% YoY
|
-5.22M
-5.22M – -5.22M
-16.2% YoY
|
| SGA |
7.40M
|
15.45M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-19.03
est: -24.11 (+21.1%)
|
-2.08
est: -2.92 (+28.8%)
|
-0.23
-0.23 – -0.23
+92.3% YoY
|
-0.24
-0.24 – -0.24
-6.7% YoY
|
-0.32
-0.32 – -0.32
-33.3% YoY
|
-0.37
-0.37 – -0.37
-15.6% YoY
|
-0.43
-0.43 – -0.43
-16.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CVI Investments, Inc. | 232.2K | 9.90% | — | 232.2K | — | 232.2K | CO | Cayman Islands | 2024-10-02 | ↗ |
| 2 | Heights Capital Management, Inc. | 232.2K | 9.90% | — | 232.2K | — | 232.2K | CO | Cayman Islands | 2024-10-02 | ↗ |
| 3 | Daniel B. Asher | 118.5K | 4.99% | — | 118.5K | — | 102.8K | HC, IN | United States of America | 2024-10-03 | ↗ |
| 4 | Intracoastal Capital LLC | 118.5K | 4.99% | — | 118.5K | — | 102.8K | OO | United States of America | 2024-10-03 | ↗ |
| 5 | Mitchell P. Kopin | 118.5K | 4.99% | — | 118.5K | — | 102.8K | HC, IN | United States of America | 2024-10-03 | ↗ |
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD FIDUCIARY TRUST CO | 241.8K +241.8K (+100.0%) | 47.4K +47.4K (+100.0%) | 1.99% +1.992 pp | 0.00% +0.000 pp | USD0.20 +0.0% | 1 qtrs NEW |
| 2 | UBS GROUP AG | 225.6K +34.2K (+17.9%) | 44.2K +4.0K (+10.0%) | 1.86% +0.282 pp | 0.00% +0.000 pp | USD0.23 -13.0% | 7 qtrs — |
| 3 | — | 192.4K +192.4K (+100.0%) | 37.7K +37.7K (+100.0%) | 1.58% +1.585 pp | 0.00% +0.000 pp | USD0.20 +0.0% | 1 qtrs NEW |
| 4 | SCHWARZ DYGOS WHEELER INVESTMENT ADVISORS LLC | 15.0K +— (+0.0%) | 2.9K -219.0 (-6.9%) | 0.12% +0.000 pp | 0.00% +0.000 pp | USD0.21 -4.8% | 2 qtrs — |
| 5 | SBI SECURITIES CO., LTD. | 131.00 +72.0 (+122.0%) | 26.00 +14.0 (+116.7%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.39 -48.7% | 6 qtrs — |
| 6 | IFP ADVISORS, INC | 11.00 +— (+0.0%) | 2.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.36 -85.3% | 7 qtrs — |
| 7 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 5.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.20 +0.0% | 2 qtrs — |
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 134.9K | 0.05% |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | Wolf Jeffrey Alan | Director | A-Award | A | Stock Options (right to buy) | 75,000 | 0.24 | 18.1K | 75,000 | D | ↗ |
| 2026-01-05 | SHALLCROSS STEVEN A | Director / Officer | A-Award | A | Stock Options (right to buy) | 475,000 | 0.24 | 114.5K | 475,000 | D | ↗ |
| 2026-01-05 | MONAHAN JOHN J | Director | A-Award | A | Stock Options (right to buy) | 75,000 | 0.24 | 18.1K | 75,000 | D | ↗ |
| 2026-01-05 | Kraws Jeffrey J | Director | A-Award | A | Stock Options (right to buy) | 75,000 | 0.24 | 18.1K | 75,000 | D | ↗ |
| 2025-04-29 | Wolf Jeffrey Alan | Director | A-Award | A | Stock Options (right to buy) | 25,000 | 1.41 | 35.4K | 25,000 | D | ↗ |
| 2025-04-29 | SHALLCROSS STEVEN A | Director / Officer | A-Award | A | Stock Options (right to buy) | 190,000 | 1.41 | 268.7K | 190,000 | D | ↗ |
| 2025-04-29 | MONAHAN JOHN J | Director | A-Award | A | Stock Options (right to buy) | 25,000 | 1.41 | 35.4K | 25,000 | D | ↗ |
| 2025-04-29 | Kraws Jeffrey J | Director | A-Award | A | Stock Options (right to buy) | 25,000 | 1.41 | 35.4K | 25,000 | D | ↗ |
| 2023-12-14 | Wolf Jeffrey Alan | Director | A-Award | A | Stock Options (right to buy) | 110,000 | 0.59 | 64.6K | 110,000 | — | ↗ |
| 2023-12-14 | SHALLCROSS STEVEN A | Director / Officer | A-Award | A | Stock Options (right to buy) | 700,000 | 0.59 | 411.3K | 700,000 | — | ↗ |
| 2023-12-14 | MONAHAN JOHN J | Director | A-Award | A | Stock Options (right to buy) | 110,000 | 0.59 | 64.6K | 110,000 | — | ↗ |
| 2023-12-14 | Kraws Jeffrey J | Director | A-Award | A | Stock Options (right to buy) | 110,000 | 0.59 | 64.6K | 110,000 | — | ↗ |
| 2023-06-07 | SHALLCROSS STEVEN A | Director / Officer | P-Purchase | A | Common Stock | 14,000 | 0.69 | 9.7K | 250,000 | — | ↗ |
| 2023-06-06 | SHALLCROSS STEVEN A | Director / Officer | P-Purchase | A | Common Stock | 26,000 | 0.63 | 16.5K | 236,000 | — | ↗ |
| 2023-02-10 | SHALLCROSS STEVEN A | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 1.04 | 26.1K | 210,000 | — | ↗ |
| 2023-02-02 | SHALLCROSS STEVEN A | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 0.94 | 23.5K | 185,000 | — | ↗ |
| 2023-01-25 | SHALLCROSS STEVEN A | Officer | P-Purchase | A | Common Stock | 25,000 | 0.87 | 21.8K | 160,000 | — | ↗ |
| 2023-01-20 | SHALLCROSS STEVEN A | Officer | P-Purchase | A | Common Stock | 25,000 | 0.75 | 18.7K | 135,000 | — | ↗ |
| 2022-12-29 | SHALLCROSS STEVEN A | Officer | P-Purchase | A | Common Stock | 100,000 | 0.44 | 43.7K | 110,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Steven A. Shallcross | Chief Executive Officer, Chief Financial Officer, Treasurer, Corporate Secretary & Director | 701.1K | male |
| Michael Kaleko | Senior Vice President of Research & Development | — | — |
| Ramon Alemany | Senior Vice President of Discovery | — | — |
| Vince Wacher | Head of Product & Corporate Development | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TOVX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
